Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the stock.

Several other equities analysts also recently weighed in on COYA. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Stock Up 0.2%

COYA stock opened at $4.22 on Monday. Coya Therapeutics has a 52 week low of $3.94 and a 52 week high of $7.75. The firm has a 50-day simple moving average of $4.68 and a 200-day simple moving average of $5.50. The stock has a market capitalization of $99.00 million, a P/E ratio of -3.32 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The company had revenue of $3.96 million during the quarter, compared to analysts’ expectations of $1.93 million. On average, analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of COYA. XTX Topco Ltd purchased a new position in Coya Therapeutics during the fourth quarter worth about $192,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at approximately $66,000. Millennium Management LLC acquired a new position in Coya Therapeutics in the fourth quarter valued at approximately $121,000. 683 Capital Management LLC acquired a new position in Coya Therapeutics in the fourth quarter valued at approximately $465,000. Finally, Cetera Investment Advisers purchased a new position in Coya Therapeutics in the fourth quarter worth approximately $128,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.